Company news

BioCardia, Inc. news in 2026

BioCardia, Inc.'s news releases, calls and decks from 2026, newest first.

View company

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter

October 19, 2026

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting

October 7, 2026

BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter

October 1, 2026

BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission

September 23, 2026

BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026

BioCardia: Aug 24 - BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-on De Novo Pre-submission For Approval

August 24, 2026

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

August 24, 2026

BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results

August 12, 2026

BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026

August 5, 2026

BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities

June 18, 2026

BioCardia Announces $4.4 Million Financing

June 7, 2026

BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure

May 28, 2026

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency

May 21, 2026

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

May 19, 2026

BioCardia Reports First Quarter 2026 Business Highlights and Financial Results

May 15, 2026

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026

May 11, 2026

BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways

May 8, 2026

BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures

April 28, 2026

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

April 20, 2026

BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure

April 1, 2026

BioCardia Reports 2025 Business Highlights and Financial Results

March 23, 2026

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

March 18, 2026

BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA

March 16, 2026

BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)

March 2, 2026

BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

February 10, 2026

BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)

February 3, 2026

Calls in 2026

Decks in 2026